Coherus Biosciences (CHRS) has released an update.
Coherus BioSciences, Inc. has expanded its Board of Directors, welcoming Georgia Erbez as a new Class III director. With a robust background in the healthcare sector, including executive roles in various biotechnology firms, Erbez brings a wealth of experience to the table. She will serve on the audit committee and, as a non-employee director, receive standard compensation including an annual retainer and a stock option grant. Her appointment strengthens the board’s expertise and underscores the company’s commitment to strong governance and financial oversight.
For further insights into CHRS stock, check out TipRanks’ Stock Analysis page.
